Evotec stock falls as JST-018 enters Phase 1

Published on 09/09/2026 at 14:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec stock closed at USD 1.82 on September 8, 2026, down 2.15 percent. MarketBeat pegs the consensus target at USD 3.00 after 4 reports.

Fotorealistisches Pharma-Labor mit Wissenschaftlern bei Wirkstoffscreening in moderner Biotech-Anlage — Fotorealistisches Pharma-Labor symbolisiert Wirkstoffforschung von Evotec SE, ISIN DE0005664809, moderner Biotech-Standort Hamburg, Illustration mit AI erstellt.

Evotec stock (DE0005664809) closed at USD 1.82 on September 8, 2026, down 2.15 percent, after trading between USD 1.80 and USD 1.83. The share price sits 40.9 percent below the January 1, 2026 level of USD 3.08, while MarketBeat puts market capitalization at USD 647.59 million.

Phase 1 study starts

According to Evotec on September 9, 2026, Just - Evotec Biologics started a Phase 1 clinical trial for JST-018, an antibody cocktail against orthopoxviruses. The company said the program was developed under the U.S. Department of War's Accelerated Antibodies Program.

The same release said the contract framework dates back to 2023 and that the two disclosed agreements together carry a potential volume of up to USD 123.9 million. It also said the orthopoxvirus program is the second project under that program and that the clinical material was manufactured at the J.POD site in Redmond.

Consensus stays cautious

MarketBeat lists 4 analyst reports, a consensus rating of Hold and a consensus target of USD 3.00 for Evotec stock on September 9, 2026. The gap to the last close is 64.8 percent, which shows how far the share price still trails the average target.

MarketBeat also shows a 52-week range of USD 1.80 to USD 4.27 and average volume of 44,236 shares, with Tuesday's volume at 64,207 shares. For investors, the 52-week low at USD 1.80 is the nearest chart reference.

Closing price stays weak

Evotec stock finished September 8, 2026 at USD 1.82 on NASDAQ EVO, with a daily range of USD 1.80 to USD 1.83 and market capitalization of USD 647.59 million. The stock remains 57.4 percent below the 52-week high of USD 4.27.